BAX Baxter International, Inc.
Baxter International, Inc. provides portfolio of essential renal and hospital products, including acute and chronic dialysis, sterile IV solutions, infusion systems and devices, parenteral nutrition therapies; premixed and oncolytic injectable, bio surgery products and anesthetics, drug reconstitution systems and pharmacy automation, software and services. It operates through the following segment: Americas, Europe, Middle East & Africa and Asia-Pacific. The company was founded by Davis Baxter in 1931 and is headquartered in Deerfield, IL.
Company profile
Ticker
BAX
Exchange
Website
CEO
José E. Almeida
Employees
Incorporated in
Location
Fiscal year end
Sector
Industry (SEC)
3M • Boston Scientific • Stryker • Becton Dickinson & Co • Teleflex • ResMed • Hill-Rom • Integra Lifesciences • AngioDynamics • NuVasive ...
SEC CIK
Corporate docs
IRS number
360781620
BAX stock data
()
Calendar
30 Apr 20
8 Jul 20
31 Dec 20
News
Company financial data Financial data
| Quarter (USD) | Mar 20 | Dec 19 | Sep 19 | Jun 19 | |
|---|---|---|---|---|---|
| Revenue | 2.8B | 3.04B | 2.85B | 2.83B | |
| Net income | 333M | -19M | 375M | 313M | |
| Diluted EPS | 0.64 | -0.05 | 0.71 | 0.6 | |
| Net profit margin | 11.88% | -0.63% | 13.15% | 11.04% | |
| Operating income | 409M | 536M | 503M | 350M | |
| Net change in cash | 775M | 326M | 75M | 1.03B | |
| Cash on hand | 4.11B | 3.34B | 3.01B | 2.93B | |
| Cost of revenue | 1.64B | 1.74B | 1.62B | 1.68B |
| Annual (USD) | Dec 19 | Dec 18 | Dec 17 | Dec 16 | |
|---|---|---|---|---|---|
| Revenue | 11.36B | 11.1B | 10.56B | 10.16B | |
| Net income | 1.01B | 1.55B | 602M | 4.97B | |
| Diluted EPS | 1.93 | 2.83 | 1.08 | 9.01 | |
| Net profit margin | 8.90% | 13.93% | 5.70% | 48.85% | |
| Operating income | 1.77B | 1.58B | 1.29B | 745M | |
| Net change in cash | 1.5B | -1.56B | 593M | 588M | |
| Cash on hand | 3.34B | 1.84B | 3.39B | 2.8B | |
| Cost of revenue | 6.6B | 6.34B | 6.11B | 6.05B |
Financial data from company earnings reports
Recent insider trades
| Date | Owner | Security | Transaction | Code | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|
| 19 Jun 20 | Accogli Giuseppe | Common Stock, $1 par value | Sell | Dispose S | Yes | 85 | 72,341 | 6.15M | 66,520 |
| 19 Jun 20 | Accogli Giuseppe | Common Stock, $1 par value | Option exercise | Aquire M | Yes | 46.18 | 8,334 | 384.86K | 76,473 |
| 19 Jun 20 | Accogli Giuseppe | Stock Option [Right to Buy) Common Stock, $1 par value | Option exercise | Dispose M | Yes | 50.77 | 62,388 | 3.17M | 31,195 |
| 19 Jun 20 | Accogli Giuseppe | Stock Option Common Stock, $1 par value | Option exercise | Dispose M | Yes | 46.18 | 8,334 | 384.86K | 0 |
| 19 Jun 20 | Accogli Giuseppe | Common Stock, $1 par value | Option exercise | Aquire M | Yes | 50.77 | 62,388 | 3.17M | 138,861 |
| 15 Jun 20 | Forsyth John D | Common Stock, $1 par value | Sell | Dispose S | No | 82.95 | 1,500 | 124.43K | 33,898 |
| 15 Jun 20 | Forsyth John D | Common Stock, $1 par value | Option exercise | Aquire M | Yes | 31.26 | 1,500 | 46.89K | 35,398 |
| 15 Jun 20 | Forsyth John D | Stock Option Common Stock, $1 par value | Option exercise | Dispose M | Yes | 31.26 | 1,500 | 46.89K | 310 |
| 8 Jun 20 | Franzi Cristiano | Common Stock, $1 par value | Sell | Dispose S | No | 87.96 | 22,700 | 2M | 39,088 |
| 8 Jun 20 | Franzi Cristiano | Common Stock, $1 par value | Sell | Dispose S | No | 87.33 | 23,900 | 2.09M | 61,788 |
Institutional ownership Q1 2020
83.5% owned by funds/institutions
13F holders |
Current |
|---|---|
| Total holders | 1076 |
| Opened positions | 76 |
| Closed positions | 126 |
| Increased positions | 291 |
| Reduced positions | 490 |
13F shares |
Current |
|---|---|
| Total value | 34.51B |
| Total shares | 424.9M |
| Total puts | 876.1K |
| Total calls | 1.13M |
| Total put/call ratio | 0.8 |
Largest owners |
Shares | Value |
|---|---|---|
| BLK BlackRock | 41.29M | $3.35B |
| Vanguard | 40.33M | $3.27B |
| Wellington Management | 29.92M | $2.43B |
| STT State Street | 23.57M | $1.92B |
| MS Morgan Stanley | 19.41M | $1.58B |
| FMR | 13.89M | $1.13B |
| Third Point | 11.58M | $940.18M |
| Generation Investment Management | 10.16M | $824.94M |
| AMP Ameriprise Financial | 9.24M | $749.79M |
| Veritas Asset Management | 8.95M | $726.89M |
Financial report summary
?Competition
ThermoGenesis • Alaris Medical Systems • rEVO Biologics • AIM ImmunoTech • Sangamo Therapeutics • Fresenius Medical Care • Alaris Medical Systems • United Health Products • Edwards Lifesciences • CurisManagement Discussion
- Net income attributable to Baxter stockholders for the three months ended March 31, 2020 totaled $332 million, or $0.64 per diluted share, compared to $342 million, or $0.66 per diluted share, for the three months ended March 31, 2019. Net income for the three months ended March 31, 2020 included special items which decreased net income by $93 million, or $0.18 per diluted share, as further discussed below. Net income for the three months ended March 31, 2019 included special items which decreased net income by $52 million, or $0.09 per diluted share, as further discussed below.
- Intangible asset amortization expense is identified as a special item to facilitate an evaluation of current and past operating performance and is consistent with how management and our Board of Directors assess performance. Additional special items are identified above because they are highly variable, difficult to predict and of a size that may substantially impact our reported results of operations for the period. Management believes that providing the separate impact of those items may provide a more complete understanding and facilitate a fuller analysis of our results of operations, particularly in evaluating performance from one period to another.
- 1In 2020 and 2019, our results were impacted by costs associated with our execution of programs to optimize our organization and cost structure on a global basis. These actions included streamlining our international operations, rationalizing our manufacturing facilities, reducing our general and administrative infrastructure, re-aligning certain R&D activities and cancelling certain R&D programs. Our results in 2020 and 2019 included business optimization charges of $32 million and $38 million, respectively. Additionally, we recognized a gain of $17 million in 2020 for property we sold in conjunction with our business optimization
Content analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. sophomore Avg
|
|
New words:
annum, compel, default, divided, doubtful, drove, event, finalize, forma, guaranteed, identical, interbank, Kingdom, LIBOR, lifetime, London, met, offer, offered, Overnight, pandemic, postponed, preliminary, pro, provision, relationship, revert, Scop, SOFR, successor, Transderm, vintage, widely
Removed:
apply, approved, ASR, assessing, Australia, bank, borrow, borrowing, BREVIBLOC, Celerity, charge, China, classify, collateralized, Committee, comparability, cooperating, determine, direct, enactment, expedient, FASB, flat, funded, guidance, ii, iii, index, LLC, maintenance, nontaxable, office, paper, practical, provisional, ranging, reclassification, seller, shorter, simplify, supplemental, Targeted, taxing, volume
Financial reports
10-Q
2020 Q1
Quarterly report
30 Apr 20
10-K
2019 FY
Annual report
17 Mar 20
10-Q
2019 Q3
Quarterly report
17 Mar 20
NT 10-K
Notice of Late Annual Filing
3 Mar 20
NT 10-Q
Notice of Late Quarterly Filing
13 Nov 19
10-Q
2019 Q2
Quarterly report
30 Jul 19
10-Q
2019 Q1
Quarterly report
8 May 19
10-K
2018 FY
Annual report
21 Feb 19
10-Q
2018 Q3
Quarterly report
5 Nov 18
10-Q
2018 Q2
Quarterly report
6 Aug 18
Current reports
8-K
Submission of Matters to a Vote of Security Holders
8 May 20
8-K
Baxter Reports First-quarter 2020 Results
30 Apr 20
8-K
Regulation FD Disclosure
21 Apr 20
8-K
Entry into a Material Definitive Agreement
27 Mar 20
8-K
Regulation FD Disclosure
23 Mar 20
8-K
Completes Financial Restatement Process
17 Mar 20
8-K
Other Events
25 Feb 20
8-K
Results of Operations and Financial Condition
13 Feb 20
8-K
Baxter Announces Preliminary Net Sales for the Fourth-quarter and Full-year 2019 and Announces Preliminary Full-year 2020 Guidance
13 Jan 20
8-K
Entry into a Material Definitive Agreement
20 Dec 19
Registration and prospectus
8-A12B
Registration of securities on exchange
15 May 19
424B2
Prospectus for primary offering
14 May 19
FWP
Free writing prospectus
10 May 19
424B5
Prospectus supplement for primary offering
10 May 19
S-3ASR
Automatic shelf registration
23 Aug 18
8-A12B
Registration of securities on exchange
30 May 17
424B2
Prospectus for primary offering
22 May 17
424B5
Prospectus supplement for primary offering
19 May 17
FWP
Free writing prospectus
19 May 17
424B5
Prospectus supplement for primary offering
12 Aug 16
Proxies
DEFA14A
Additional proxy soliciting materials
21 Apr 20
DEFA14A
Additional proxy soliciting materials
31 Mar 20
DEFA14A
Additional proxy soliciting materials
17 Mar 20
DEF 14A
Definitive proxy
17 Mar 20
DEFA14A
Additional proxy soliciting materials
26 Mar 19
DEF 14A
Definitive proxy
26 Mar 19
DEF 14A
Definitive proxy
23 Mar 18
DEFA14A
Additional proxy soliciting materials
23 Mar 18
DEF 14A
Definitive proxy
17 Mar 17
DEFA14A
Additional proxy soliciting materials
17 Mar 17
Other
SD
Conflict minerals disclosure
1 Jun 20
SD
Conflict minerals disclosure
24 May 19
SD
Conflict minerals disclosure
31 May 18
SD
Conflict minerals disclosure
31 May 17
CERTNYS
Certification of approval for NYSE listing
30 May 17
UPLOAD
Letter from SEC
10 May 17
CORRESP
Correspondence with SEC
28 Apr 17
CORRESP
Correspondence with SEC
14 Apr 17
UPLOAD
Letter from SEC
31 Mar 17
NO ACT
No action letter
27 Dec 16
Ownership
4
BAXTER INTERNATIONAL / Giuseppe Accogli ownership change
23 Jun 20
4
BAXTER INTERNATIONAL / JOHN D FORSYTH ownership change
17 Jun 20
4
BAXTER INTERNATIONAL / Cristiano Franzi ownership change
10 Jun 20
4
BAXTER INTERNATIONAL / Andrew Frye ownership change
5 Jun 20
4
BAXTER INTERNATIONAL / Amy McBride Wendell ownership change
7 May 20
4
BAXTER INTERNATIONAL / ALBERT P L STROUCKEN ownership change
7 May 20
4
BAXTER INTERNATIONAL / THOMAS T STALLKAMP ownership change
7 May 20
4
BAXTER INTERNATIONAL / Cathy R Smith ownership change
7 May 20
4
BAXTER INTERNATIONAL / Stephen N. Oesterle ownership change
7 May 20
4
BAXTER INTERNATIONAL / PATRICIA MORRISON ownership change
7 May 20
Patents
GRANT
Utility
Packaging system and methods of alerting a practitioner
7 Jul 20
A packaging system includes a container having a closed end an open end, a longitudinal axis running through the closed end and the open end, and an outer surface.
GRANT
Utility
Drain and fill logic for automated peritoneal dialysis
7 Jul 20
A system for performing a peritoneal dialysis therapy includes at least one dialysis fluid pump, and a logic implementer operable with the at least one dialysis fluid pump to perform a plurality of peritoneal dialysis cycles, the cycles including a fill phase, a dwell phase and a drain phase, the logic implementer configured to: (i) store a first peritoneal dialysis treatment having a total prescribed fresh dialysis fluid fill volume delivered over a number of cycles; and (ii) convert the first peritoneal dialysis treatment into a second peritoneal dialysis treatment having a different number of cycles and using the same total prescribed fresh dialysis fluid fill volume.
GRANT
Utility
Renal therapy machine and method including a priming sequence
30 Jun 20
A method for priming a renal therapy machine is disclosed.
APP
Utility
Dialysis System Including Dextrose Mixing
11 Jun 20
An automated peritoneal dialysis system and machine configured to perform dextrose mixing are disclosed.
APP
Utility
Apparatus for Extracorporeal Treatment of Blood and Method of Priming an Extracorporeal Blood Circuit
11 Jun 20
An extracorporeal blood treatment apparatus comprises: a blood treatment device (2); an extracorporeal blood circuit comprising a blood withdrawal line (6) and a blood return line (7) coupled to the extracorporeal blood treatment device (2), wherein the blood return line (7) presents a heating zone (14) coupled or configured to be coupled to a blood warmer (15); a blood pump (6) configured to be coupled to a pump section of the blood withdrawal line (6); at least a post-infusion line (13, 13′) connected to the blood return line (7) upstream of the heating zone (14); an air trapping device (9) placed on the blood return line (7) upstream of the heating zone (14).